Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Ironwood Pharmaceuticals (IRWD) over the last 17 years, with Q3 2025 value amounting to $140.4 million.

  • Ironwood Pharmaceuticals' Cash & Current Investments rose 5917.18% to $140.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $140.4 million, marking a year-over-year increase of 5917.18%. This contributed to the annual value of $88.6 million for FY2024, which is 390.11% down from last year.
  • Per Ironwood Pharmaceuticals' latest filing, its Cash & Current Investments stood at $140.4 million for Q3 2025, which was up 5917.18% from $92.9 million recorded in Q2 2025.
  • In the past 5 years, Ironwood Pharmaceuticals' Cash & Current Investments registered a high of $741.6 million during Q1 2023, and its lowest value of $88.2 million during Q3 2024.
  • In the last 5 years, Ironwood Pharmaceuticals' Cash & Current Investments had a median value of $176.1 million in 2023 and averaged $334.1 million.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first surged by 9801.85% in 2021, then plummeted by 8598.42% in 2023.
  • Quarter analysis of 5 years shows Ironwood Pharmaceuticals' Cash & Current Investments stood at $621.4 million in 2021, then increased by 5.81% to $657.5 million in 2022, then tumbled by 85.98% to $92.2 million in 2023, then decreased by 3.9% to $88.6 million in 2024, then soared by 58.55% to $140.4 million in 2025.
  • Its last three reported values are $140.4 million in Q3 2025, $92.9 million for Q2 2025, and $108.5 million during Q1 2025.